PAMIPARIB HYDRATE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C16H15FN4O.3H2O
Molecular Weight	650.6756
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.O.C[C@]12CCCN1CC3=NNC(=O)C4=C5C(NC2=C35)=CC(F)=C4.C[C@]67CCCN6CC8=NNC(=O)C9=C%10C(NC7=C8%10)=CC(F)=C9

InChI

InChIKey=DSUDUMUXDPNRBY-WWUGNDHESA-N

InChI=1S/2C16H15FN4O.3H2O/c2*1-16-3-2-4-21(16)7-11-13-12-9(15(22)20-19-11)5-8(17)6-10(12)18-14(13)16;;;/h2*5-6,18H,2-4,7H2,1H3,(H,20,22);3*1H2/t2*16-;;;/m11.../s1

HIDE SMILES / InChI

Molecular Formula	C16H15FN4O
Molecular Weight	298.3149
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Poly [ADP-ribose] polymerase-1 23 Target ID: CHEMBL3105 Sources: https://www.beigene.com/science-and-product-portfolio/pipeline/pamiparib \| https://cancerres.aacrjournals.org/content/75/15_Supplement/1653 \| https://patents.google.com/patent/WO2013097225A1	Inhibitor 8504		0.83 nM [IC50]
Poly [ADP-ribose] polymerase 2 16 Target ID: CHEMBL5366 Sources: https://www.beigene.com/science-and-product-portfolio/pipeline/pamiparib \| https://cancerres.aacrjournals.org/content/75/15_Supplement/1653 \| https://patents.google.com/patent/WO2013097225A1	Inhibitor 8504		0.11 nM [IC50]

C_max

Value	Dose	Analyte	Population
74.5 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
181.7 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	2.5 mg 2 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
193.1 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
404.2 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	5 mg 2 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
412 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
656.8 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	10 mg 2 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
782.7 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1267.6 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	20 mg 2 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1754.7 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2940.9 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1881.4 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3832.4 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2317.8 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4352.3 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	80 mg 2 times / day steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3586.5 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4532.3 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	120 mg 2 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3752.8 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6059.1 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5336 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6872.7 ng/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	160 mg 1 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
718.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33128299/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
1280.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33128299/	20 mg 2 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
1633.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33128299/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
5213.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33128299/	40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
2302.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33128299/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
5861.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33128299/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
384.7 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
931.3 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	2.5 mg 2 times / day multiple, oral dose: 2.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1099.2 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2117.9 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	5 mg 2 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2576 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4327.2 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	10 mg 2 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4134.9 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7512.3 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	20 mg 2 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8954.8 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
18297.5 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10403.7 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
25218.6 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13213 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
25276.6 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	80 mg 2 times / day steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
21101.2 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
26862.7 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	120 mg 2 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
21725.1 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
36558.4 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
31820.5 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
45264.4 ng × h/mL EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	160 mg 1 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4129.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33128299/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
8357.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33128299/	20 mg 2 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
8557.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33128299/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
32469.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33128299/	40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
11895.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33128299/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
38135.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33128299/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
12.03 h EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.01 h EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
14.08 h EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.53 h EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.76 h EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.5 h EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.58 h EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10.91 h EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
14.29 h EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
15.25 h EXPERIMENT https://www.nature.com/articles/s41416-021-01632-2#MOESM2	160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33128299/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
11.79 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33128299/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
13.77 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33128299/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	PAMIPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
4.3% EXPERIMENT https://link.springer.com/article/10.1007/s40265-021-01552-8	single, oral		PAMIPARIB plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN

PubMed

Title	Date	PubMed
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.	2019-09	31378459

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:36:30 GMT 2025` Edited by `admin` on `Mon Mar 31 23:36:30 GMT 2025`
Record UNII	BV047JVV2S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BGB-290 HYDRATE

Preferred Name

English

PAMIPARIB HYDRATE

Common Name

English

Code System Code Type Description

FDA UNII

BV047JVV2S

Created by admin on Mon Mar 31 23:36:30 GMT 2025 , Edited by admin on Mon Mar 31 23:36:30 GMT 2025

PRIMARY

CAS

1858211-28-5

Created by admin on Mon Mar 31 23:36:30 GMT 2025 , Edited by admin on Mon Mar 31 23:36:30 GMT 2025

PRIMARY

PUBCHEM

135566123

Created by admin on Mon Mar 31 23:36:30 GMT 2025 , Edited by admin on Mon Mar 31 23:36:30 GMT 2025

PRIMARY

Related Record Type Details


					8375F9S90C

PAMIPARIB

ANHYDROUS->SOLVATE


					8375F9S90C

PAMIPARIB

PARENT -> SALT/SOLVATE

Related Record Type Details


					8375F9S90C

PAMIPARIB

ACTIVE MOIETY

Details

SMILES

InChI

Approval Year

Targets

Cmax

AUC

T1/2

Funbound

PubMed

Patents

C_max

T_1/2

F_unbound